Pre-Made Balugrastim Biosimilar, Fusion Protein targeting CSF3R/G-CSF-R fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting CD114/GCSFR/SCN7 for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Balugrastim Biosimilar, Fusion Protein targeting CSF3R/G-CSF-R fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting CD114/GCSFR/SCN7 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Balugrastim has been used in trials studying the treatment of Solid Tumors. Neutropenia is one of the most common toxicities in cancer patients receiving myelosuppressive chemotherapy. Patients who develop neutropenia are at increased risk for infection with fever. Balugrastim is a recombinant granulocyte colony-stimulating factors (G-CSFs) reduce the incidence and duration of chemotherapy-induced neutropenia and febrile neutropenia when given as adjunct therapy to patients receiving myelosuppressive chemotherapy. Balugrastim is a long-acting G-CSF composed of a genetic fusion between recombinant human serum albumin and G-CSF.
| Products Name (INN Index) | Pre-Made Balugrastim Biosimilar, Fusion Protein targeting CSF3R/G-CSF-R fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting CD114/GCSFR/SCN7 |
|---|---|
| INN Name | balugrastim |
| Target | CSF3R |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | Fusion – ALB (albumin, human serum albumin, HSA) 25-609 – CSF3 (colony stimulating factor 3, GCSF, granulocyte colony-stimulating factor, G-CSF) |
| VD LC | Fusion – ALB (albumin, human serum albumin, HSA) 25-609 – CSF3 (colony stimulating factor 3, GCSF, granulocyte colony-stimulating factor, G-CSF) |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | GlaxoSmithKline (Brentford UK) / Teva Pharmaceutical Industries?Ltd (Cephalon) (Frazer PA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CSF3R |
| Package |
